A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer
- 12 October 2017
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 67 (2) , 183-193
Abstract
Colorectal cancer is a deadly disease, which is frequently diagnosed at advanced stages, where conventional treatments are no longer effective. Cancer immunotherapy has emerged as a new form to treat different malignancies by turning-on the immune system against tumors. However, tumors are able to evade antitumor immune responses by promoting an immunosuppressive microenvironment. Single-stranded DNA containing M13 bacteriophages are highly immunogenic and can be specifically targeted to the surface of tumor cells to trigger inflammation and infiltration of activated innate immune cells, overcoming tumor-associated immunosuppression and promoting antitumor immunity. Carcinoembryonic antigen (CEA) is highly expressed in colorectal cancers and has been shown to promote several malignant features of colorectal cancer cells. In this work, we targeted M13 bacteriophage to CEA, a tumor-associated antigen over-expressed in a high proportion of colorectal cancers but largely absent in normal cells. The CEA-targeted M13 bacteriophage was shown to specifically bind to purified CEA and CEA-expressing tumor cells in vitro. Both intratumoral and systemic administration of CEA-specific bacteriophages significantly reduced tumor growth of mouse models of colorectal cancer, as compared to PBS and control bacteriophage administration. CEA-specific bacteriophages promoted tumor infiltration of neutrophils and macrophages, as well as maturation dendritic cells in tumor-draining lymph nodes, suggesting that antitumor T-cell responses were elicited. Finally, we demonstrated that tumor protection provided by CEA-specific bacteriophage particles is mediated by CD8+ T cells, as depletion of circulating CD8+ T cells completely abrogated antitumor protection. In summary, we demonstrated that CEA-specific M13 bacteriophages represent a potential immunotherapy against colorectal cancer.Keywords
Funding Information
- Comisión Nacional de Investigación Científica y Tecnológica (PFB-16)
- Comisión Nacional de Investigación Científica y Tecnológica (CL) (791100038)
- Corporación de Fomento de la Producción (INNOVA 12IDL2-13348)
- Fondo Nacional de Desarrollo Científico y Tecnológico (1171703, 3130764)
This publication has 49 references indexed in Scilit:
- Immunological basis of M13 phage vaccine: Regulation under MyD88 and TLR9 signalingBiochemical and Biophysical Research Communications, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Intracellular DNA recognitionNature Reviews Immunology, 2010
- The Yin-Yang of Tumor-Associated NeutrophilsCancer Cell, 2009
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Colorectal Hyperplasia and Dysplasia Due to Human Carcinoembryonic Antigen (CEA) Family Member Expression in Transgenic MicePLOS ONE, 2007
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cellsJournal of Clinical Investigation, 2006
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- Immunological properties of foreign peptides in multiple display on a filamentous bacteriophageGene, 1993
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculeCell, 1989